Development and evaluation of co-formulated docetaxel and curcumin biodegradable nanoparticles for parenteral administration

References

• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751–760
   PubMed Web of Science ®Google Scholar
• Waterhouse DN, Gelmon KA, Klasa R, et al. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets 2006;6:455–489
   PubMed Web of Science ®Google Scholar
• DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64:52–62
   PubMed Web of Science ®Google Scholar
• Venishetty VK, Parikh N, Sistala R, et al. Application of validated RP-HPLC method for simultaneous determination of docetaxel and Ketoconazole in solid lipid nanoparticles. J Chromatogr Sci 2011;49:136–141
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Z, Liu D, et al. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm 2011;413:194–201
   PubMed Web of Science ®Google Scholar
• Jinturkar KA, Anish C, Kumar MK, et al. Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials 2012;33:2492–2507
   PubMed Web of Science ®Google Scholar
• Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem 2007;2:920–942
   Web of Science ®Google Scholar
• Zhan Y, Chen Y, Liu R, et al. Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling. Arch Pharmacal Res 2014;37:1086–1095
   PubMed Web of Science ®Google Scholar
• Mohan PR, Sreelakshmi G, Muralidharan CV. Water soluble complexes of curcumin with cyclodextrins: characterization by FT-Raman spectroscopy. Vib Spectrosc 2012;62:77–84
   Web of Science ®Google Scholar
• Bill MA, Baken C, Benson DM, et al. Curcumin induces pro-apoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther 2009;8:2726–2735
   PubMed Web of Science ®Google Scholar
• Gaurisankar SA, Das T. Anti cancer effects of curcumin: cycle of life and death. Cell Division 2008;3:14
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interf Sci 2010;351:19–29
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005;11:7490–7498
   PubMed Web of Science ®Google Scholar
• Averineni RK, Shavi GV, Gurram AK, et al. PLGA 50:50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. Bull Mater Sci 2012;35:319–326
   Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161:505–522
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010;75:1–18
   PubMed Web of Science ®Google Scholar
• Zhou YZ, Alany RG, Chuang V, Wen J. Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design. Drug Dev Ind Pharm 2013;39:321–330
   PubMed Web of Science ®Google Scholar
• Woodcock J. The concept of pharmaceutical quality. Am Pharm Rev 2004;7:10–15
   Google Scholar
• US FDA. Guidance for industry: PAT-A framework for innovative pharmaceutical development, manufacturing, and quality assurance. Silver Spring, MD: US FDA; 2004
   Google Scholar
• Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic “design of experiments”. Part I: fundamental aspects. Crit RevTher Drug 2005;22:27–105
   PubMed Web of Science ®Google Scholar
• Upadhyay KK, Bhatt AN, Castro E, et al. In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol Biosci 2010;10:503–512
   PubMed Web of Science ®Google Scholar
• Li X, Wang D, Zhang J, Pan W. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers. J Pharm Pharmacol 2009;61:1485–1492
   PubMed Web of Science ®Google Scholar
• Singare DS, Marella S, Gowthamrajan K, et al. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm 2010;402:213–220
   PubMed Web of Science ®Google Scholar
• Kwon HY, Lee JY, Choi SW, et al. Preparation of PLGA nanoparticles containing estrogen by emulsification–diffusion method. Colloid Surface B 2001;30:123–130
   Web of Science ®Google Scholar
• GC Na, Rajagopalan N. Use of charged phospholipids to reduce nanoparticle aggregation. US Patent 5,336,507, Google Patents, 1994
   Google Scholar
• Papadopoulou V, Kosmidis K, Vlachou M, Macheras P. On the use of the weibull function for the discernment of drug release mechanisms. Int J Pharm 2006;309:44–50
   PubMed Web of Science ®Google Scholar
• Podczeck F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). Int J Pharm 1993;97:93–100
   Web of Science ®Google Scholar
• Rivolta I, Panariti A, Lettiero B, et al. Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles. J Physiol Pharmacol 2011;62:45–53
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep 2013;3:1–8
   Web of Science ®Google Scholar
• Italia J, Yahya M, Singh D, Kumar MR. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone®. Pharm Res 2009;26:1324–1331
   PubMed Web of Science ®Google Scholar
• Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 2000;17:100–106
   PubMed Web of Science ®Google Scholar
• Huang X, Zhou C, Wang H, et al. Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex. AAPS PharmSciTech 2011;12:665–672
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev 2003;55:329–347
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere™). Ann Oncol 1993;4:610–611
   PubMed Web of Science ®Google Scholar
• Avgoustakis K, Beletsi A, Panagi Z, et al. PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 2002;79:123–135
   PubMed Web of Science ®Google Scholar